syndrome of decreased NCC activity, Gitelman's syndrome [3, 4] . In 2001, mutations in the with-no-lysine (K) (WNK) kinases, WNK1 and WNK4, were linked to FHHt [5] . This family of kinases was given the designation WNK as they lack a strictly conserved lysine residue with the catalytic domain [6] . They range in size from 1200 to 1700 amino acids, and their sequences are highly conserved between species [7, 8] . WNK1, WNK3, and WNK4 are expressed in the DCT, and in addition, a shorter transcript of WNK1 lacking its kinase domain is expressed exclusively in the kidney [kidney-specific WNK1 (ks-WNK1)] [7, 8] .
The discovery of a link between the WNK kinases and FHHt gave way to a flurry of studies [9, 10] using the Xenopus laevis oocyte expression system that described a cascade of inhibitory effects involving WNK kinases and NCC. NCC activity was inhibited by WNK4, WNK1 inhibited WNK4's effect, and ks-WNK1 inhibited full length WNK1 [11] [12] [13] [14] . The role of the kinase and protein-protein interaction domains in these activities is unclear, with various studies having produced conflicting results [11, 12] . The changes in activity are mediated by changes in NCC surface expression, as coexpression of WNK4 and enhanced green fluorescent protein (EGFP)-NCC has demonstrated reduced NCC cell surface expression in the presence of WNK4 [12, 15] . Further studies [15, 16] using both oocytes and transfected mammalian cells demonstrated that WNK4's effect on NCC was dynamin independent, and therefore not mediated by clathrin-mediated endocytosis. WNK4 enhanced lysosomal degradation of NCC [15] . Recent work has shown that WNK4 sharply decreases movement of NCC from the trans-Golgi network to the plasma membrane, with NCC instead accumulating in lysosomes [17 ] . Furthermore, NCC was shown to associate with the adaptor protein AP-3, which is involved in lysosomal transport [17 ] . The addition of WNK4 enhanced this association, suggesting that WNK4 stimulates NCC-AP3 interaction, thereby stimulating NCC's transport to the lysosome [17 ] . Notably, this study represents the first reported use of an externally tagged NCC to measure surface expression.
Recent work has described a role for WNK3 in the regulation of NCC. WNK3 has been shown to stimulate NCC activity, with kinase-dead WNK3 having an inhibitory effect on the cotransporter [18] . WNK3 antagonizes the action of WNK4, and vice versa, with FHHt diseasecausing mutants exerting a dominant negative effect on WNK4's ability to oppose WNK3, creating a state of effective WNK3 excess [19] . In addition, WNK3 was associated with both WNK4 and WNK1, and ks-WNK1 inhibited WNK3's kinase activity [19] . Through use of chimeras, these effects of WNK3 and WNK4 have been shown to be dependent on their amino-terminal domains [20 ] . These interesting studies should form the basis for future investigations utilizing transgenic animal models or mammalian cells, or both to further characterize the role of WNK3 in NCC regulation.
The cell models demonstrating inhibition of NCC by WNK4 and loss of function of WNK4 FHHt mutants have now been supported by a transgenic whole animal model. Mice transgenic for these WNK4 mutations developed hypertension that was remediable with thiazide diuretics, thus recapitulating the clinical syndrome of FHHt [21] . In addition, mice transgenic for an additional normal WNK4 gene exhibited hypotension when compared with wildtype mice [21] . These data reinforced the cell-based data. Echoing the results of the prior animal study, another group created a different FHHt WNK4 mutant knockin mouse that developed hypertension treatable with thiazide diuretics [22] . This study demonstrated an increased NCC phosphorylation as well as phosphorylation of two recently described stimulators of NCC activity, STE20/selenophosphate synthetase 1 (SPS-1)-related proline/alanine-rich kinase and oxidative stress-responsive kinase-1 (SPAK and OSR1). These data led the authors to hypothesize that wild-type WNK4 acts through SPAK/ OSR1 to increase NCC activity, and that the WNK4 mutation is a gain-of-function mutation [22] .
Regulation of sodium-chloride cotransporter by oxidative stress-responsive kinase-1/ STE20/selenophosphate synthetase 1-related proline/alanine-rich kinase OSR1 and SPAK are closely related kinases belonging to the STE20 kinase subfamily, possessing a conserved serine motif and C-terminal domain [23] [24] [25] . Immunoprecipitation and yeast two-hybrid studies revealed that WNK1 and WNK4 interact with SPAK and OSR1 [24, [26] [27] [28] . The SPAK/OSR1-conserved C-terminal domain interacts with specific RFx(V/I) motifs present on the WNK kinases [25, 27, 28] . Both WNK1 and WNK4 have been shown to phosphorylate OSR1 and SPAK at a Thr residue (Thr233 in SPAK/Ser323 in OSR1) and a Ser residue (Ser 373 in SPAK/Ser323 in OSR1) [24] . Although both have been shown to phosphorylate and activate SPAK/OSR1, WNK1 may be more efficient at phosphorylating OSR1/SPAK than WNK4 (at least in vitro) [24] . This link between WNKs and SPAK/OSR appears to be quite important, as this pathway is evolutionarily conserved from nematodes to humans [29] .
A long recognized phenomenon has been the ability of hypotonicity or low-chloride concentration, or both to enhance the activity of NCCs [30, 31] . In fact, all three of the sodium-dependent cation-chloride cotransporters are phosphorylated in their amino terminus and activated in response to low-chloride concentration or hypotonicity, or both [25, [32] [33] [34] . It is now evident that SPAK and OSR1 are responsible for this phosphorylation and activation. Recent studies have demonstrated that SPAK/ OSR1 phosphorylates NCC at three specific residues, that is, Thr46, Thr55, and Thr60 in human NCC [35 ] . Exposure of human embryonic kidney 293 (HEK293) and mpkDCT cells to hypotonic, low-chloride incubation enhances NCC phosphorylation at those three sites [35 ] . Interaction at an N-terminal RFxI motif appears to facilitate phosphorylation [35 ] . Of these sites, Thr60 is of particular importance. Mutation of Thr60 to a nonphosphorylatable Ala results in decreased phosphorylation at each of the three residues, implying a central role for Thr60 in this process [35 ] . Furthermore, mutation of Thr60 sharply decreased NCC activity in response to low-chloride incubation in both mammalian cells and oocytes [35 ,36] . Interestingly, mutations of Thr60 have been associated with Gitelman's syndrome, the genetic disorder of hypotension secondary to a lossof-function mutation of NCC [37] .
Although this WNK-SPAK-NCC stimulatory pathway is consistent with the data indicating that WNK1 stimulates NCC at baseline and that FHHt-causing WNK1 mutations are gain-of-function mutations, it implies a different pathway to this effect. It remains to be seen whether this pathway or WNK4 inhibition by WNK1 is the primary physiologic pathway by which WNK1 stimulates NCC. It is possible that these two pathways operate in parallel, providing dual mechanisms of action ( Fig. 1) . Importantly, unlike WNK4, there is no available transgenic animal model to study the effects of mutant WNK1. Mice heterozygous for a gene-trapping WNK1 mutation (WNK1 deficient) did display decreased blood pressure (BP) compared with controls, but a homozygous WNK1 gene-trap mutation was embryonic lethal [38] .
The WNK4-SPAK-NCC cell-based data indicating that WNK4 stimulates NCC have been considerably more controversial, as there is a body of data indicating that WNK4 inhibits NCC. This was further examined in an FHHt-causing WNK4 mutant knock-in mouse that was found to have a hypertensive and hyperkalemic phenotype compared with wild-type animals [22] . These mice displayed increased phosphorylation of both NCC and SPAK/OSR1 [22] . Therefore, the authors hypothesized that wild-type WNK4 acts through SPAK/OSR1 to phosphorylate and increase the surface expression of NCC, and that mutant WNK4 is a gain-of-function mutation [22] . This hypothesis is in opposition to the wealth of data, indicating that wild-type WNK4 decreases NCC surface expression and mutant WNK4 is a loss-of-function mutation (Fig. 1) [11, 12, 21] . The two animals are transgenic for different FHHt mutations (WNK4 D561A for this study vs. WNK4 Q562E ), and it has not been reported whether the mouse generated by Lalioti et al. [21] also has altered phosphorylation of NCC. Two recent studies [39 ,40 ] exploring hormonal mechanisms of NCC regulation have provided hints that may eventually reconcile these seemingly disparate hypotheses. These studies suggest that WNK4 may stimulate NCC function through SPAK only under certain physiologic or hormonal conditions.
Regulation of sodium-chloride cotransporter by hormones and other mechanisms
Although aldosterone has traditionally been thought to mediate physiologic effects on sodium reabsorption and BP through regulation of epithelial sodium channel (ENaC), a number of studies [41] [42] [43] have shown that it also regulates NCC. This would be consistent with the expression of the mineralocorticoid receptors in the DCT of humans, rats, and rabbits [44] [45] [46] . Recent work has suggested a role for OSR1/SPAK in an aldosterone effect on NCC (Fig. 2) [39 ] . In wild-type mice, increased phosphorylation of NCC and OSR1/SPAK was seen with low-salt diets, an effect blocked by spironolactone [39 ] . Administration of exogenous aldosterone recapitulated this effect [39 ] . However, the previously described WNK4 FHHt knock-in mouse demonstrated increased phosphorylation that was not effected by a low-salt diet or aldosterone. Function of NCC was not measured in this study. These findings implied that under conditions of renin-angiotensin-aldosterone stimulation, aldosterone mediates increased phosphorylation of SPAK and NCC. FHHt mutations seem to render this phosphorylation constitutive.
Angiotensin II (AII) has also been implicated as a potential regulator of the WNK-SPAK-NCC stimulatory cascade. Studies [47, 48] have demonstrated that AII acutely increases the surface expression of NCC in the rat DCT, and that angiotensin-converting enzyme inhibitors blocked the increase in surface expression. A very recent study [40 ] indicated that coinjection of AII receptors, NCC, and WNK4 into Xenopus oocytes followed by exposure to AII resulted in an increase in thiazide-sensitive 22 Na þ uptake as compared with NCC and WNK4 alone. Exposure to AII appeared to prevent the inhibition of WNK4. In this system, AII had no effect on NCC function in the absence of WNK4. A SPAK dominant negative prevented the effect of AII in the presence of WNK4 (Fig. 2) . Additionally, this study showed a qualitative increase in SPAK and NCC phosphorylation in mammalian cells exposed to AII. These studies suggest that under certain physiologic conditions that activate the renin-angiotensin-aldosterone system, WNK4 may indeed be stimulatory for NCC and perhaps under other physiologic conditions, WNK4 inhibits NCC. Future studies should further clarify the effects of angiotensin and aldosterone on WNK4, SPAK, and NCC in whole animal and mammalian cell models. Figure 1 Contrasting theories into the mechanism of familial hyperkalemic hypertension mutations (a) Mutant WNK4 as a loss of function. WNK4 acts to inhibit NCC activity. Mutant WNK4 is unable to inhibit NCC, resulting in a net increase in NCC activity. (b) Mutant WNK4 as a gain of function. In the normal state, WNK4 activates OSR1/SPAK, which in turn activates NCC, resulting in enhanced NCC activity. The mutant WNK4 is a gain of function mutation, resulting in increased OSR1/SPAK activation and therefore increased NCC activity. (c) Mutant WNK1 acting via WNK4. WNK1 normally acts to inhibit WNK4. As WNK4 inhibits NCC, this has the net result of increasing NCC activity. Mutant WNK1 is a gain of function, enhancing its ability to inhibit WNK4 and therefore increasing NCC activity. (d) Mutant WNK1 acting via OSR1/SPAK. WNK1 normally acts to increase OSR1/SPAK phosphorylation, which increases NCC activity. Mutant WNK1 is a gain of function mutation, resulting in increased OSR1/SPAK activity, which in turn increases NCC activity. NCC, sodium-chloride cotransporter; OSR1, oddskipped-related 1; SPAK, Ste20-related proline/alanine-rich kinase; WNK, with-nolysine.
In addition, NCC's role in pressure natriuresis has been examined, with AII as a mediator. Distal tubule salt reabsorption (and presumably NCC activity) decreases in response to acute increases in BP [49 ] . In this study [49 ] , AII was found to blunt the diuretic effect. However, in a second study [50 ] , using a rat arterial constriction model of acute hypertension, NCC expression at the apical surface (presumed to be a surrogate for NCC activity) was shown to decrease in response to acute increases in BP. Clamping AII at a constant level prevented this effect, suggesting that NCC retraction from the apical membrane contributes to pressure natriuresis and that this effect is mediated (at least in part) by a decrease in AII [50 ] . These seemingly disparate results may be in fact due to a number of possible factors. As the first study did not separate NCC and ENaC activity, differential effects on NCC and ENaC in pressure diuresis could account for the differences. Similarly, potential biphasic dose effects of AII on NCC (the studies used vastly different doses of AII) and differences in experimental models (AII infusion vs. vasoconstrictive) may play a role in the contrasting results.
Lastly, work in our laboratory has uncovered an additional kinase pathway that regulates NCC activity [51] . Using a mammalian cell line with native NCC activity, phorbol esters, an analog of diacylglycerol, markedly diminished NCC activity. Although diacylglerol (DAG) has been historically linked to activation of protein kinase C (PKC), utilizing specific inhibitors and RNA interference, we were able to demonstrate a more complex interaction. Phorbol esters stimulate Ras guanyl nucleotide-releasing protein 1 (RasGRP1), which activates the small G-protein Ras, triggering a cascade ultimately activating extra-cellular signal-regulated kinases 1 and 2-mitogen-activated protein kinase (ERK1/2-MAPK) (Fig. 2) . ERK1/2 activation then triggers reduced NCC activity [51] . Our recent data (unpublished observations) have suggested that ERK1/2 activation enhances ubiquitination of NCC, in turn triggering endocytosis of NCC. As DAG activation is often associated with G-protein-coupled receptor activation, this pathway may mediate the effects of various hormones on NCC.
Thiazide-sensitive Na-Cl cotransporter Ko and Hoover 425 Binding of ligand to G-protein coupled (aq) receptor stimulates PLCb. PLCb activation triggers DAG release, in turn stimulating RasGRP1, Ras, Raf, MEK1/2, and ERK1/2. ERK1/2 causes enhanced ubiquitination of NCC, ultimately reducing NCC activity. WNK4 appears to directly inhibit NCC activity. WNK1 and WNK3 appear to inhibit WNK4. WNK3 may directly activate NCC as well. WNK1 and WNK4 stimulate OSR1/SPAK. OSR1/ SPAK activates NCC. Stimulation of the mineralcorticoid receptor, or AIIR, or both may act through WNK4 to activate OSR1/SPAK (Ã, under certain hormonal/physiologic stimuli, WNK4 acts to stimulate OSR1/SPAK), stimulating NCC. AIIR, angiotensin II receptor; DAG, diacylglerol; ERK, extracellular signal-related kinase; MR, mineralcorticoid receptor; NCC, sodium-chloride cotransporter; OSR1, oxidative stress-responsive kinase-1; PLCb, phospholipase C beta; RasGRP1, Ras guanyl nucleotide-releasing protein 1; SPAK, Ste20-related proline/alanine-rich kinase.
Conclusion
The past 2 years have seen a remarkable increase in our understanding of the molecular regulation of NCC (Fig. 2) . Another WNK kinase (WNK3) has been found to interact with and regulate NCC and WNK4, adding another layer of complexity to an intricate pathway. Additionally, two other kinases (SPAK and OSR1) have now been implicated as key stimulators of NCC activity and potential transducers of WNK signaling to NCC. Two mice transgenic for different WNK4 FHHt mutations have demonstrated thiazide-sensitive hypertension. However, one of those transgenic mice has demonstrated increased phosphorylation of NCC at SPAK phosphorylation sites. This suggested that WNK4 may be able to activate NCC, and that certain WNK4 mutations could result in increased activation of SPAK and thus NCC. However, a wealth of data indicates that WNK4 inhibits NCC, and that the FHHt mutation is a gain of function. These data may be reconciled by very recent studies, indicating that WNK4 may be stimulatory for NCC only under certain hormonal or physiologic conditions. Further studies examining whether WNK4 can both activate NCC via SPAK and inhibit NCC directly depending on the conditions will be essential to advancing the field. On the contrary, all WNK1 studies seem to indicate that WNK1 stimulates NCC. Further studies are necessary to determine whether WNK1 stimulates NCC through WNK4 inhibition and SPAK activation in a parallel fashion or whether one of these pathways is the more physiologically relevant one. Phorbol ester stimulation of RasGRP1 revealed that ERK1/2 is yet another kinase that inhibits NCC activity, and this may be an important pathway for G-protein-coupled hormone receptor regulation of NCC. Importantly, the investigation of the molecular physiology of NCC has now begun to focus on the hormonal regulation of NCC. This key step in our understanding of the physiology of NCC is still in its infancy, but the process of understanding the role and mechanism of AII and aldosterone effects on NCC has begun. Future work will focus on clarifying these controversies and further exploring these pathways.
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